 "Sun Pharma to test pancreatitis drug in Covid-19 patients in India")
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in Covid-19 patients.
The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for Covid-19, which currently has no approved treatment or vaccine.
Sun Pharma said here the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for Covid-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany".
The company said it has initiated manufacturing of the active pharmaceutical ingredient (API) and the finished product of the drug using technology from its unit, Pola Pharma Japan.
In April, the University of Tokyo announced plans for a trial of nafamostat mesilate and camostat mesilate, a related drug, licensed in Japan and South Korea to treat chronic pancreatitis.
Sun Pharma shares gained after the announcement, and closed up 3.3% at 474.25 rupees. Shares in Indian drugmakers have been on a tear this year, with the Nifty pharma index rising 21.5% so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%